ىاسمىن

المعلومات الرئيسية

  • اسم تجاري:
  • ىاسمىن
  • الشكل الصيدلاني:
  • FILM COATED TABLETS
  • طريقة التعاطي:
  • PER OS
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • المخدرات الوباتشيك
  • المصنعة من قبل:
  • BAYER PHARMA AG, GERMANY

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • ىاسمىن
    إسرائيل
  • اللغة:
  • العربية

معلومات العلاجية

  • المجموعة العلاجية:
  • DROSPIRENONE AND ESTROGEN
  • الخصائص العلاجية:
  • Oral contraception.

معلومات أخرى

الحالة

  • المصدر:
  • Ministry of Health - State of Israel
  • تخويل:
  • 122023022000
  • تاريخ الترخيص:
  • 01-04-2011
  • اخر تحديث:
  • 09-08-2016
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

6-3-2018

Methylprednisolone Sodium Succinate for Injection 40mg, 125mg, and 1g by Sagent Pharmaceuticals: Recall - High Out of Specification Impurity Results

Methylprednisolone Sodium Succinate for Injection 40mg, 125mg, and 1g by Sagent Pharmaceuticals: Recall - High Out of Specification Impurity Results

An elevated impurity has the potential to decrease effectiveness of the product in patients. Posted: 03/06/2018

FDA - U.S. Food and Drug Administration

26-2-2018

FDA Drug Safety Communication: FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia

FDA Drug Safety Communication: FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia

[03-06-2014] The U.S. Food and Drug Administration (FDA) has concluded that Doribax (doripenem), an antibacterial drug that has been used to treat patients who develop pneumonia while on ventilators, carries an increased risk of death and lower clinical cure rates compared to use of imipenem and cilastatin for injection (marketed in the U.S. under the name Primaxin).

FDA - U.S. Food and Drug Administration

13-2-2018

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy

[11-03-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Tumor Necrosis Factor (TNF) blockers and malignancy (cancer) in children, adolescents, and young adults (30 years of age or younger).

FDA - U.S. Food and Drug Administration

9-2-2018

FDA Drug Safety Communication: Safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone

FDA Drug Safety Communication: Safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone

[09-26-2011] The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills.

FDA - U.S. Food and Drug Administration

19-1-2018

Scientific guideline:  Guideline on the chemistry of active substances for veterinary medicinal products, adopted

Scientific guideline: Guideline on the chemistry of active substances for veterinary medicinal products, adopted

Guideline concerning the application of Directive 2001/82/EC with a view to the granting of a marketing authorisation for a veterinary medicinal product. This guideline replaces the ‘Note for guidance on chemistry of new active substances’ (EMEA/CVMP/541/03/Final) and ‘Chemistry of active substances’ (3AQ5a). It has been revised to cover new and existing active substances in one guideline.

Europe - EFSA - European Food Safety Authority EFSA Journal

3-1-2018

Enforcement Report for the Week of January 03, 2018

Enforcement Report for the Week of January 03, 2018

FDA - U.S. Food and Drug Administration

13-12-2017

FDA Drug Safety Communication: Updated information about the FDA-funded study on risk of blood clots in women taking birth control pills containing drospirenone

FDA Drug Safety Communication: Updated information about the FDA-funded study on risk of blood clots in women taking birth control pills containing drospirenone

[10-27-2011] The U.S. Food and Drug Administration (FDA) is continuing its review of the potential increased risk of blood clots with the use of birth control pills containing drospirenone.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use

FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use

[03-03-2015] The U.S. Food and Drug Administration (FDA) cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking

FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking

[03-09-2015] The U.S. Food and Drug Administration (FDA) is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: FDA review of study sheds light on two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate)

FDA Drug Safety Communication: FDA review of study sheds light on two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate)

[03-23-2015] The U.S. Food and Drug Administration (FDA) has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate) in two patients who died.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients

[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: Safety Review of possible increased risk of blood clots with birth control pills containing drospirenone

FDA Drug Safety Communication: Safety Review of possible increased risk of blood clots with birth control pills containing drospirenone

[05-31-2011] The U.S. Food and Drug Administration (FDA) is informing the public about new information that is being assessed as part of FDA's ongoing safety review of birth control pills that contain drospirenone.

FDA - U.S. Food and Drug Administration

21-5-2018

EU/3/14/1353 (Lupin Europe GmbH)

EU/3/14/1353 (Lupin Europe GmbH)

EU/3/14/1353 (Active substance: Mexiletine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)3134 of Mon, 21 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/074/14/T/03

Europe -DG Health and Food Safety

18-5-2018

EU/3/04/204 (Gilead Sciences Ireland UC)

EU/3/04/204 (Gilead Sciences Ireland UC)

EU/3/04/204 (Active substance: Aztreonam lysinate (inhalation use)) - Transfer of orphan designation - Commission Decision (2018)3131 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMEA/OD/006/04/T/03

Europe -DG Health and Food Safety

16-5-2018

EU/3/06/391 (Novartis Europharm Limited)

EU/3/06/391 (Novartis Europharm Limited)

EU/3/06/391 (Active substance: Amphotericin B (for inhalation use)) - Transfer of orphan designation - Commission Decision (2018)3034 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/027/06/T/03

Europe -DG Health and Food Safety

16-5-2018

EU/3/03/140 (Novartis Europharm Limited)

EU/3/03/140 (Novartis Europharm Limited)

EU/3/03/140 (Active substance: Tobramycin (inhalation powder)) - Transfer of orphan designation - Commission Decision (2018)3031 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMEA/OD/072/02/T/02

Europe -DG Health and Food Safety

3-5-2018

Avamys (Glaxo Group Ltd)

Avamys (Glaxo Group Ltd)

Avamys (Active substance: Fluticasone furoate) - Centralised - Yearly update - Commission Decision (2018)2773 of Thu, 03 May 2018

Europe -DG Health and Food Safety

3-5-2018

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Active substance: pramipexole) - Centralised - Yearly update - Commission Decision (2018)2775 of Thu, 03 May 2018

Europe -DG Health and Food Safety

3-5-2018

Hemlibra (Roche Registration GmbH)

Hemlibra (Roche Registration GmbH)

Hemlibra (Active substance: emicizumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2774 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4406/T/1

Europe -DG Health and Food Safety

3-5-2018

Remsima (Celltrion Healthcare Hungary Kft.)

Remsima (Celltrion Healthcare Hungary Kft.)

Remsima (Active substance: Infliximab) - Centralised - Yearly update - Commission Decision (2018)2769 of Thu, 03 May 2018

Europe -DG Health and Food Safety

3-5-2018

Clopidogrel Zentiva (Zentiva, k.s.)

Clopidogrel Zentiva (Zentiva, k.s.)

Clopidogrel Zentiva (Active substance: Clopidogrel) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2776 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/975/T/60

Europe -DG Health and Food Safety

3-5-2018

Entresto (Novartis Europharm Limited)

Entresto (Novartis Europharm Limited)

Entresto (Active substance: sacubitril / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2779 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4062/T/18

Europe -DG Health and Food Safety

3-5-2018

Trisenox (Teva B.V.)

Trisenox (Teva B.V.)

Trisenox (Active substance: Arsenic trioxide) - Centralised - Yearly update - Commission Decision (2018)2778 of Thu, 03 May 2018

Europe -DG Health and Food Safety

17-4-2018

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Active substance: Ornithine phenylacetate) - Transfer of orphan designation - Commission Decision (2018)2355 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/105/11/T/03

Europe -DG Health and Food Safety

5-4-2018

LO-ZUMANDIMINE (Drospirenone And Ethinyl Estradiol) Kit [Aurobindo Pharma Limited]

LO-ZUMANDIMINE (Drospirenone And Ethinyl Estradiol) Kit [Aurobindo Pharma Limited]

Updated Date: Apr 5, 2018 EST

US - DailyMed

3-4-2018

EU/3/12/1080 (AbbVie Deutschland GmbH and Co. KG)

EU/3/12/1080 (AbbVie Deutschland GmbH and Co. KG)

EU/3/12/1080 (Active substance: 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) - Transfer of orphan designation - Commission Decision (2018)2056 of Tue, 03 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/124/12/T/01

Europe -DG Health and Food Safety

28-3-2018

EU/3/04/241 (Roche Registration GmbH)

EU/3/04/241 (Roche Registration GmbH)

EU/3/04/241 (Active substance: Pirfenidone) - Transfer of orphan designation - Commission Decision (2018)2006 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/OD/052/04/T/03

Europe -DG Health and Food Safety

22-3-2018

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Apotex Corp.]

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Apotex Corp.]

Updated Date: Mar 22, 2018 EST

US - DailyMed

20-3-2018

SYEDA (Drospirenone And Ethinyl Estradiol) Kit [Xiromed, LLC.]

SYEDA (Drospirenone And Ethinyl Estradiol) Kit [Xiromed, LLC.]

Updated Date: Mar 20, 2018 EST

US - DailyMed

20-2-2018

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [A-S Medication Solutions]

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [A-S Medication Solutions]

Updated Date: Feb 20, 2018 EST

US - DailyMed

9-2-2018

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Mylan Pharmaceuticals Inc.]

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Mylan Pharmaceuticals Inc.]

Updated Date: Feb 9, 2018 EST

US - DailyMed

6-2-2018

EU/3/07/478 (ICON Clinical Research Limited)

EU/3/07/478 (ICON Clinical Research Limited)

EU/3/07/478 (Active substance: N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide) - Transfer of orphan designation - Commission Decision (2018)697 of Tue, 06 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/053/07/T/03

Europe -DG Health and Food Safety

5-2-2018

EU/3/07/526 (ICON Clinical Research Limited)

EU/3/07/526 (ICON Clinical Research Limited)

EU/3/07/526 (Active substance: N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide) - Transfer of orphan designation - Commission Decision (2018)698 of Mon, 05 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/099/07/T/03

Europe -DG Health and Food Safety

23-1-2018

VESTURA (Drospirenone And Ethinyl Estradiol) Kit [Actavis Pharma, Inc.]

VESTURA (Drospirenone And Ethinyl Estradiol) Kit [Actavis Pharma, Inc.]

Updated Date: Jan 23, 2018 EST

US - DailyMed

22-12-2017

3LAB PERFECT BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc]

3LAB PERFECT BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc]

Updated Date: Dec 22, 2017 EST

US - DailyMed

22-12-2017

3LAB AQUA BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc.]

3LAB AQUA BB SPF 40 BROAD SPECTRUM 03 (Titanium Dioxide) Cream [3LAB, Inc.]

Updated Date: Dec 22, 2017 EST

US - DailyMed

22-12-2017

SYEDA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

SYEDA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

Updated Date: Dec 22, 2017 EST

US - DailyMed

18-12-2017

 Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Minutes - Enpr-EMA Coordinating Group and networks meeting, Wednesday 25 October 2017, EMA room 03-H and via Adobe Connect; 15.00 to 17:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

Agenda:  Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Agenda: Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017

Agenda - Enpr-EMA Coordinating Group and networks meeting, Wednesday 25 October 2017, EMA room 03-H and via Adobe Connect; 15.00 to 17:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

Agenda:  Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Agenda: Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Agenda - Enpr-EMA Coordinating Group meeting, Wednesday 22 November 2017, EMA room 03-H and via Adobe Connect; 15.00 to 16:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

 Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting

Minutes - Enpr-EMA Coordinating Group meeting, Wednesday 22 November 2017, EMA room 03-H and via Adobe Connect; 15.00 to 16:00 UK time

Europe - EMA - European Medicines Agency

18-12-2017

ZARAH (Drospirenone And Ethinyl Estradiol) Kit [Mayne Pharma Inc.]

ZARAH (Drospirenone And Ethinyl Estradiol) Kit [Mayne Pharma Inc.]

Updated Date: Dec 18, 2017 EST

US - DailyMed

12-12-2017

EU/3/05/272 (Noventia Pharma Srl)

EU/3/05/272 (Noventia Pharma Srl)

EU/3/05/272 (Active substance: Histamine dihydrochloride) - Transfer of orphan designation - Commission Decision (2017)8597 of Tue, 12 Dec 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/094/04/T/03

Europe -DG Health and Food Safety

6-12-2017

Summer Skin Risks: Sunburn, Bug Bites & Poison Ivy

Summer Skin Risks: Sunburn, Bug Bites & Poison Ivy

Title: Summer Skin Risks: Sunburn, Bug Bites & Poison IvyCategory: MedicineNet QuizCreated: 8/17/2010 12:00:00 AMLast Editorial Review: 12/6/2017 6:04:03 PM

US - MedicineNet

21-11-2017

LORYNA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

LORYNA (Drospirenone And Ethinyl Estradiol) Kit [Sandoz Inc]

Updated Date: Nov 21, 2017 EST

US - DailyMed

7-11-2017

NIKKI ( Drospirenone And Ethinyl Estradiol ) Kit [Lupin Pharmaceuticals, Inc.]

NIKKI ( Drospirenone And Ethinyl Estradiol ) Kit [Lupin Pharmaceuticals, Inc.]

Updated Date: Nov 7, 2017 EST

US - DailyMed

26-10-2017

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Pharmaceutics International, Inc. (Pii)]

DROSPIRENONE AND ETHINYL ESTRADIOL Kit [Pharmaceutics International, Inc. (Pii)]

Updated Date: Oct 26, 2017 EST

US - DailyMed

25-10-2017

Insomnia Quiz: What Is Insomnia?

Insomnia Quiz: What Is Insomnia?

Title: Insomnia Quiz: What Is Insomnia?Category: MedicineNet QuizCreated: 6/6/2016 12:00:00 AMLast Editorial Review: 10/25/2017 2:47:03 PM

US - MedicineNet

17-10-2017

LUMASILK EMULSION LEVEL 03 Emulsion [The Skin Atelier, Inc.]

LUMASILK EMULSION LEVEL 03 Emulsion [The Skin Atelier, Inc.]

Updated Date: Oct 17, 2017 EST

US - DailyMed